TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
COSCIENS Biopharma ( (TSE:CSCI) ) has provided an update.
On May 13, 2025, COSCIENS Biopharma Inc. released its condensed interim consolidated financial statements for the first quarter of 2025. The report highlights a net loss of $3,655,000 for the quarter, with significant changes in shareholders’ equity and a decrease in total assets compared to the previous quarter. The company is undergoing strategic shifts, including the sunsetting of certain programs and focusing on the development of its PGX Technology and completion of its Edmonton and Natex Termitz facilities. These developments are expected to impact the company’s financial position and market strategy.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc., formerly known as Aeterna Zentaris Inc., operates in the biopharmaceutical industry. The company focuses on the development and commercialization of patented technologies and value-driving products, including active ingredients extracted from natural sources, oat-based pipeline products, and pharmaceutical therapeutic assets. Its market focus includes addressing unmet needs within the nutraceuticals markets and the commercialization of Macrilen® (macimorelin).
Average Trading Volume: 2,116
Technical Sentiment Signal: Sell
Current Market Cap: C$14.5M
See more insights into CSCI stock on TipRanks’ Stock Analysis page.